SEATTLE (

TheStreet

) --The U.S. agency in charge of Medicare has scheduled a meeting for Nov. 17 to discuss the use of

Dendreon's

TST Recommends

(DNDN)

prostate cancer vaccine Provenge.

The meeting announcement was posted Tuesday on the

web site of the Centers for Medicare and Medicaid Services (CMS)

.

"The Centers for Medicare and Medicaid Services (CMS) has called this meeting to consider the currently available evidence regarding the impact of labeled and unlabeled use of autologous cellular immunotherapy treatment on health outcomes of patients with metastatic prostate cancer," the agency's announcement stated.

In June, CMS announced that it was opening an

assessment to determine a national coverage decision of Provenge

, which received FDA approval earlier this year as a treatment for advanced prostate cancer.

Since that announcement, Dendreon has indicated that

14 of the 15 regional Medicare carriers are either already reimbursing patients for Provenge

or have signaled their intention to do so. Strong demand for Provenge in the form of patients on waiting lists to receive the drug has also been reported by the company.

Dendreon shares closed Tuesday up 15 cents to $35.84.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.